Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $54.50 Consensus PT from Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $54.50.

Several research analysts have weighed in on ORKA shares. Jefferies Financial Group initiated coverage on shares of Oruka Therapeutics in a research report on Thursday, November 13th. They issued a “buy” rating and a $45.00 price target on the stock. BTIG Research lifted their target price on Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Piper Sandler began coverage on Oruka Therapeutics in a research report on Thursday, December 18th. They set an “overweight” rating and a $75.00 price objective on the stock.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the sale, the insider owned 34,018 shares in the company, valued at approximately $1,101,162.66. This represents a 17.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 21,000 shares of company stock valued at $663,530 in the last three months. Corporate insiders own 24.69% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

Several large investors have recently made changes to their positions in the business. Legal & General Group Plc bought a new stake in Oruka Therapeutics in the 2nd quarter worth approximately $28,000. Ameritas Investment Partners Inc. purchased a new position in shares of Oruka Therapeutics in the second quarter valued at $31,000. BNP Paribas Financial Markets increased its position in Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares during the last quarter. Royal Bank of Canada raised its stake in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in Oruka Therapeutics during the fourth quarter valued at $37,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics Stock Up 0.3%

Shares of NASDAQ:ORKA opened at $34.41 on Wednesday. The stock has a market capitalization of $1.67 billion, a PE ratio of -18.11 and a beta of -0.38. The firm’s 50 day moving average price is $32.26 and its 200-day moving average price is $26.16. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $36.53.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.